MAP1LC3A and Alzheimer disease: To further validate the correlation between autophagy activation and DAU’s anti-AD effect, we co-administered DAU with the autophagy inhibitor 10 μM 3-methyladenine (3-MA, MCE, New Jersey, USA), which primarily inhibits Class PI3K-III activity and prevents autophagosome formation and LC3 expression [27].